Insight Molecular Diagnostics Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Insight Molecular Diagnostics Inc. (formerly Oncocyte, now trading as iMDx) performed this year. My goal is to cut through the corporate jargon so you can decide if this company fits your portfolio.

1. What does this company do?

iMDx focuses on precision medicine, specifically transplant diagnostics and oncology. They provide lab services and diagnostic kits that help doctors make better care decisions. Their technology monitors transplant health and detects cancer recurrence. They recently rebranded their tests, such as VitaGraft, to names like GraftAssureCore and GraftAssureDx. These tests use gene analysis to give doctors clear data on organ rejection or tumor growth.

2. Financial Performance & Health

The 2024 fiscal year shows a company in a difficult transition. They brought in about $12.5 million in revenue, a slight increase from last year. However, they remain far from making a profit, reporting a $38 million loss.

• The Cash Situation: As of December 31, 2024, the company held about $8.2 million in cash. They spend roughly $7–$9 million every quarter, so they rely on outside investors to stay afloat. They often sell more shares to raise money. This keeps the company running but reduces your ownership percentage in the business.
• The "Going Concern" Risk: The company admits there is "substantial doubt" about its ability to stay in business. They are running out of money. Management says they need $25 million to $35 million in the next year to avoid cutting operations or filing for bankruptcy.

3. Major Wins and Challenges

• Strategic Rebranding: The company is moving from a high-cost service model to a more scalable "kit" model. By rebranding under the GraftAssure name, they hope to make it easier for hospital labs to use their products. They aim to grow adoption by 15–20% each year.
• Customer Concentration: A major red flag is that two partners provide 40% of their revenue. Losing one of these partners would create a massive hole in their income and could cause them to default on their debts.
• Partnerships: They rely heavily on Bio-Rad Laboratories to sell their products. While this helps with credibility, it means iMDx’s success depends on Bio-Rad’s marketing. iMDx earns a cut of sales but cannot control the pricing or sales strategy.

4. Key Risks

• Dilution: Because the company frequently issues more shares to raise cash, your "slice of the pie" shrinks. Last year, the number of shares grew by 25%, which lowers the potential value of your investment.
• Regulatory Hurdles: They depend on government regulators and insurance companies. A major risk is the "reimbursement gap"—the time between launching a test and getting insurance to pay for it. If an insurer denies coverage, the company loses up to 60% of a test's potential revenue.
• Market Competition: They compete against giants like Natera and Eurofins. If a competitor offers a faster or cheaper test, iMDx could lose its remaining market share.

5. Future Outlook

The path forward is steep. iMDx must prove it can become profitable before its cash runs out. Management aims to cut costs by 30% while increasing test volume by 40% in 2025. Success depends entirely on finding new funding or a partner to provide cash, as their current funds will not last through the year.

---

Investor Takeaway: iMDx is currently in a high-risk "survival mode." The company is burning through cash faster than it is generating revenue, and the reliance on share dilution to fund operations is a significant headwind for long-term shareholders. Before considering an investment, look for clear evidence that they have secured the $25–$35 million in funding they need to bridge their operations through 2025.